Related Experiment Video
Updated: Dec 11, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Evolution of tumor cells during AsiDNA treatment results in energy exhaustion, decrease in responsiveness to signal,
Pierre-Marie Girard1,2, Nathalie Berthault1,2, Maria Kozlac1,2
1Institut Curie CNRS INSERM UMR 3347 PSL Research University Orsay France.
Abstract:
It is increasingly suggested that ecological and evolutionary sciences could inspire novel therapies against cancer but medical evidence of this remains scarce at the moment. The Achilles heel of conventional and targeted anticancer treatments is intrinsic or acquired resistance following Darwinian selection; that is, treatment toxicity places the surviving cells under intense evolutionary selective pressure to develop resistance. Here, we review a set of data that demonstrate that Darwinian principles derived from the "smoke detector" principle can instead drive the evolution of malignant cells toward a different trajectory. Specifically, long-term exposure of cancer cells to a strong alarm signal, generated by the DNA repair inhibitor AsiDNA, induces a stable new state characterized by a down-regulation of the targeted pathways and does not generate resistant clones. This property is due to the original mechanism of action of AsiDNA, which acts by overactivating a "false" signaling of DNA damage through DNA-PK and PARP enzymes, and is not observed with classical DNA repair inhibitors such as the PARP inhibitors. Long-term treatment with AsiDNA induces a new "alarm down" state in the tumor cells with decrease in NAD level and reactiveness to it. These results suggest that agonist drugs such as AsiDNA could promote a state-dependent tumor cell evolution by lowering their ability to respond to high "danger" signal. This analysis provides a compelling argument that evolutionary ecology could help drug design development in overcoming fundamental limitation of novel therapies against cancer due to the modification of the targeted tumor cell population during treatment.
Insights
Novel cancer therapies inspired by evolutionary ecology show promise. Long-term treatment with AsiDNA, a DNA repair inhibitor, induces a stable "alarm down" state in cancer cells, preventing resistance development.
Area of Science:
- Evolutionary biology
- Cancer research
- Drug discovery
Background:
- Conventional cancer treatments face limitations due to acquired resistance driven by Darwinian selection.
- Ecological and evolutionary principles offer potential for novel therapeutic strategies against cancer.
Purpose of the Study:
- To explore how Darwinian principles can guide cancer evolution towards non-resistant trajectories.
- To investigate the effects of long-term exposure to the DNA repair inhibitor AsiDNA on cancer cells.
Main Methods:
- Review of data demonstrating cancer cell evolution under specific selective pressures.
- Analysis of AsiDNA's mechanism of action involving DNA-PK and PARP enzymes.
- Observation of cancer cell response to long-term AsiDNA treatment, including NAD levels.
Main Results:
- Long-term AsiDNA exposure induces a stable "alarm down" state in cancer cells, characterized by pathway down-regulation.
- This treatment strategy does not generate resistant cancer clones, unlike conventional therapies.
- AsiDNA overactivates "false" DNA damage signaling via DNA-PK and PARP, distinct from PARP inhibitors.
Conclusions:
- AsiDNA acts as an agonist drug, promoting state-dependent tumor cell evolution by reducing their response to danger signals.
- Evolutionary ecology principles can inform drug design to overcome treatment resistance in cancer therapies.
- This approach offers a promising avenue for developing more effective and durable cancer treatments.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...